Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Biosimilar ABP 798 Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  February 13, 2019

A clinical trial in RA patients has established the pharmacokinetic similarity of ABP 798 and rituximab…

Filed under:Biologics/DMARDsDrug Updates

Ibuprofen an Option for Early Pain Control after Hip Replacement

Reuters Staff  |  February 13, 2019

NEW YORK (Reuters Health)—Combining paracetamol (acetaminophen) with ibuprofen does not cut postoperative use of morphine in a clinically meaningful way relative to ibuprofen alone, in patients undergoing total hip arthroplasty (THA), results of a Danish randomized trial suggest. “Although the combined use of paracetamol and ibuprofen reduced immediate postoperative morphine consumption compared with paracetamol alone…

Filed under:AnalgesicsDrug Updates Tagged with:hiphip arthroplastyIbuprofenPainPain Managementsurgerytotal hip arthroplastytotal hip replacement

Moments That the Words Don’t Reach

Philip Seo, MD, MHS  |  February 12, 2019

There are moments that the words don’t reach There is suffering too terrible to name You hold your child as tight as you can And push away the unimaginable                                     —Lin Manuel Miranda A friend of mine was killed a few days ago. By the time you read this column, the scars will have already started…

Filed under:OpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:bereavementgriefsudden bereavementsudden death

Update & Changes to the OIG Work Plan

From the College  |  February 8, 2019

Early last fall, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) released its OIG Work Plan for fiscal year 2018–2019, which is a two-year framework for the audits, inspections, evaluations and investigative activities planned in support of its vision, mission, and strategic goals and objectives to maintain HHS program integrity….

Filed under:From the CollegePractice Support Tagged with:evaluation and management (E/M)HHS programMedicare AdvantageMedicare paymentsOffice of Inspector General (OIG)OIG Work PlanOpioid misuse

RA Effectiveness Differs Among Non-TNF Inhibitors

Will Boggs, MD  |  February 5, 2019

NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) outcomes are better with some non-TNF inhibitors than with others, according to French registry data. “Previously, indirect comparisons (meta-analyses) did not show any difference between biologics in terms of effectiveness,” Dr. Jacques-Eric Gottenberg from Strasbourg University Hospital, France, tells Reuters Health by email. “Our direct comparison using observational data…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptnon-TNF inhibitorsRheumatoid Arthritis (RA)rituximabtocilizumab

Walking Ability of OA Patients Linked to Cardiovascular Risk

Arthritis Care & Research  |  February 5, 2019

New research explores the association of the ability to walk and the risk of cardiovascular disease in OA patients compared with the general population. During the study, researchers recorded a six-minute walking distance and measured arterial stiffness of participants. The results: Even among younger people, OA patients could not walk as far as those in the general population. Also, arterial stiffness was inversely associated with walking distance, suggesting walking is important to the cardiovascular risk profile of OA patients…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis Care & ResearchCardiovascular diseaseOsteoarthritisphysical activityriskwalking

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2019

Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…

Filed under:AnalgesicsDrug Updates Tagged with:Biologics & BiosimilarsBiosimilarsCanadaetanerceptFDAgeneric drug marketnaloxoneopioidOpioid abusePsoriatic ArthritisU.S. Food and Drug Administration (FDA)

U.S. Lawmaker Yarmuth Says Democrats to Begin Medicare for All Hearings

Yasmeen Abutaleb and Susan Cornwell  |  January 31, 2019

WASHINGTON (Reuters)—Democrats in control of the U.S. House of Representatives will begin holding hearings on expanding Medicare this spring and will aim to pass a bill by the end of next year, a senior Democratic lawmaker said on Tuesday. John Yarmuth, chairman of the House Budget Committee, said in an interview with Reuters that the…

Filed under:Legislation & Advocacy Tagged with:John YarmuthMedicare expansionMedicare for Allsingle-payer system

What Do JIA Patients Experience? A New Case Study from the ARP Practice Committee

Talitha Cox, OT, MA, on behalf of the ARP Practice Committee  |  January 31, 2019

What does a new patient experience as symptoms develop and diagnosis is confirmed? The ARP Practice Committee is developing persona-based case studies to help answer this and other questions. The latest topic is juvenile idiopathic arthritis…

Filed under:Conditions Tagged with:ARP Practice CommitteeAssociation of Rheumatology Professionals (ARP)case reportJIAJuvenile Arthritis (JIA)Juvenile idiopathic arthritis

FDA Advisory Committee Votes in Favor of Romosozumab Approval

Michele B. Kaufman, PharmD, BCGP  |  January 30, 2019

An FDA advisory committee voted 18-1 in favor of approving romosozumab to treat postmenopausal women with osteoporosis.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:boneFDAOsteoporosisromosozumabU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 132
  • 133
  • 134
  • 135
  • 136
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences